The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

Conference on HIV Science officially opened Monday in the Rwandan capital of Kigali, with a strong call to accelerate access to long-acting HIV prevention and treatment innovations amid growing global ...

The World Health Organization (WHO) is recommending a twice-yearly injection of lenacapavir for prevention of HIV, according to a press release .

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

The World Health Organization (WHO) released today new guidelines recommending the use of injectable lenacapavir (LEN) twice ...

Scientists, researchers, policy makers and HIV/AIDS advocates at a meeting in Kigali, Rwanda, from July 13-17 for the 13th International AIDS Conference on HIV Science (IAS 2025), have raised an alarm ...

New data from Africa and Latin America shows rising infections, stalled treatment, and strained health systems Kampala, Uganda | RONALD MUSOKE | Scientists, researchers, policy makers and HIV/AIDS ...

Global progress against AIDS is at risk as US funding cuts threaten life-saving programs. Experts warn of millions of ...

The World Health Organization now recommends lenacapavir, a twice-yearly injectable HIV prevention drug, especially for high-risk groups. This endorsement arrives amidst funding concerns, with Gilead ...